Welcome to our dedicated page for Neurosense Therapeutics SEC filings (Ticker: NRSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroSense Therapeutics Ltd. filings document foreign private issuer disclosures for a clinical biotechnology company developing PrimeC for severe neurodegenerative diseases. Its Form 6-K reports cover clinical and regulatory updates, PrimeC patent protection, scientific publication of PARADIGM trial results, Nasdaq continued-listing notifications, and incorporation of selected reports into Form S-8 and Form F-3 registration statements.
The company’s regulatory record also addresses shareholder voting matters, including amendments to registered share capital, capital-structure disclosures, governance changes, material agreements, operating and financial results, and leadership or advisory arrangements tied to the PrimeC development program.
NeuroSense Therapeutics reported full-year 2025 results and highlighted major progress for its ALS drug candidate PrimeC. The Phase 2b study showed about 33% slowing in disease progression over 18 months, and follow-up survival data indicated a 65% reduction in risk of death with more than a 14‑month median survival benefit. PrimeC received FDA clearance in November 2025 to initiate the PARAGON Phase 3 ALS trial, and results were published in JAMA Neurology.
Financially, 2025 research and development expenses were $6.2 million and general and administrative expenses were $4.9 million, leading to a net loss of $11.1 million, or $0.44 per share. As of December 31, 2025, cash and cash equivalents were $166 thousand, down from $3.4 million a year earlier, and shareholders’ equity stood at a deficit of $1.6 million.
NeuroSense Therapeutics Ltd. reports in its annual filing that it is a clinical-stage biotech focused on PrimeC for ALS, with no approved products and no material revenue. As of December 31, 2025, it held $0.2 million in cash and cash equivalents and recorded a $11.1 million net loss for 2025, following a $10.2 million net loss in 2024. Its auditors include a going concern reference, as the company will require substantial additional financing to continue operations, complete clinical trials, obtain regulatory approvals and commercialize its pipeline. The company highlights significant risks around funding, clinical and regulatory uncertainty, intense competition in neurodegenerative diseases, reliance on third-party manufacturers and CROs, and protection of its intellectual property. NeuroSense recently shifted its accounting framework to U.S. GAAP and is preparing a pivotal Phase 3 trial of PrimeC for ALS after receiving FDA clearance, while also exploring an expedited approval pathway with Health Canada.
Russek-Blum Niva reported acquisition or exercise transactions in this Form 4 filing.
NeuroSense Therapeutics Ltd. reported that Chief Technology Officer Niva Russek-Blum received a grant of 200,000 Ordinary Shares. These are restricted shares awarded as compensation at a stated price of $0.00 per share, increasing her direct holdings to 467,953 Ordinary Shares after the grant.
The restricted shares vest in equal quarterly installments over a two-year period, starting from the grant date of March 26, 2026, and depend on her continued service with the company. Footnotes note that, to qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the company’s 2018 Share Incentive Plan must be registered in the name of a trustee.
NeuroSense Therapeutics Ltd. Chief Technology Officer Niva Russek-Blum filed an initial ownership report showing multiple equity holdings in the company. The filing lists 36,000 options to purchase ordinary shares at an exercise price of $2.18 per share, fully vested and exercisable, expiring on January 25, 2032.
It also reports several blocks of ordinary shares, including 39,881 shares, 35,000 shares and 183,072 shares held directly, plus 10,000 restricted share units. Footnotes note that certain restricted shares vest mostly in April 2027 with the remainder in October 2027, while the restricted share units vest on April 1, 2026, all subject to continued service and, for some awards, a business milestone.
NeuroSense Therapeutics Ltd. filed an initial ownership report showing that Chief Executive Officer and 10% owner Alon Ben-Noon holds several blocks of ordinary shares and warrants. He directly holds 3,175,266 Ordinary Shares, plus additional direct holdings of 641,524 and 360,777 Ordinary Shares. He also holds warrants to purchase 26,666 Ordinary Shares at an exercise price of $0.75 per share, expiring on August 14, 2029, and warrants to purchase 80,000 Ordinary Shares at an exercise price of $1.25 per share, expiring on December 4, 2029. Footnotes explain that these warrants and related shares were acquired in private placements on August 15, 2024 and December 5, 2024, and that certain restricted shares vest 75% on April 16, 2027 and May 19, 2027, with the remainder vesting later in 2027, subject to continued service and a business milestone.
Binder Hagit reported acquisition or exercise transactions in this Form 4 filing.
NeuroSense Therapeutics Ltd. granted General Manager Hagit Binder 200,000 Ordinary Shares as a share-based compensation award, recorded at a price of $0.0000 per share. Following this grant, Binder directly holds 521,806 Ordinary Shares.
The award consists of restricted shares that vest in equal quarterly installments over a two-year period starting on March 26, 2026, conditioned on Binder’s continued service with the company at each vesting date. To qualify for certain Israeli tax benefits under Section 102, the securities must be registered in the name of a trustee, but they are reported here as directly owned by Binder.
NeuroSense Therapeutics furnished a report describing regulatory and clinical progress for its lead drug candidate, PrimeC, targeting ALS and Alzheimer’s disease. A pre-New Drug Submission meeting with Health Canada has been rescheduled to May 2026 so the company can include additional clinical, biomarker and survival data, aiming to strengthen its case under Canada’s conditional approval pathway (NOC/c).
The company also expects to report clinical and biomarker results from its Alzheimer’s study in the coming weeks. Management believes the enhanced data package and upcoming readouts could support a more constructive regulatory dialogue and mark important potential value inflection points across its ALS and Alzheimer’s programs during 2026.
NeuroSense Therapeutics Ltd. director Christine A. Pellizzari filed an initial ownership report showing existing equity interests rather than new trades. The filing lists options to purchase 72,000 Ordinary Shares at an exercise price of $1.43 per share, expiring on March 10, 2032, which are fully vested and exercisable. It also discloses direct holdings of Ordinary Shares, including restricted shares that vest on December 30, 2026 and January 30, 2027, subject to continued service and achievement of specified business milestones.
NeuroSense Therapeutics Ltd. Chief Medical Officer Tracik Ferenc filed a Form 3 disclosing his existing equity stake in the company. The filing lists fully vested options to purchase 108,000 Ordinary Shares at an exercise price of $3.51 per share, expiring on October 31, 2031, and warrants to purchase 66,667 Ordinary Shares at an exercise price of $0.75 per share, expiring on August 14, 2029. It also notes direct holdings of Ordinary Shares and includes restricted shares that vest in 2027 or earlier upon achieving a specified business milestone.
NeuroSense Therapeutics Ltd. director Mark Leuchtenberger filed an initial ownership report showing his existing equity position in the company. The filing lists options to purchase 192,000 ordinary shares at an exercise price of $3.51 per share, expiring on October 31, 2031, which are fully vested and exercisable.
He also reports direct holdings of ordinary shares in several blocks, including 128,000 shares, 75,000 shares, and 122,951 restricted shares. Some of these restricted shares are scheduled to vest on December 30, 2026 and January 30, 2027, subject to his continued service and the achievement of specified business milestones.